An Open Label, Multi-center Nilotinib Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Nilotinib Study and Are Judged by the Investigator to Benefit From Continued Nilotinib Treatment
Phase of Trial: Phase IV
Latest Information Update: 17 Jul 2019
At a glance
- Drugs Nilotinib (Primary)
- Indications Cancer; Gastrointestinal stromal tumours
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novartis; Novartis Pharmaceuticals
- 08 Jul 2019 This trial has been completed in France.
- 10 Oct 2018 This trial has been completed in Slovakia.
- 10 May 2018 Planned End Date changed from 18 Dec 2023 to 28 Apr 2023.